U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA's counterfeit mitigation initiatives and product verification and testing programs specific to FSC 5962 microcircuits. The maximal value of the indefinite delivery contract is $1.04 million over an up to five-year performance term. The option-year exercise continues Applied DNA's support of DLA's counterfeit mitigation program, which has been running since 2014.
應用DNA科學公司（Applied DNA Sciences, Inc.，納斯達克代碼：APDN）是PCR基礎DNA技術領域的領先者，總部位於紐約州Stony Brook，今天宣佈美國國防物資局（DLA）行使了自2021年5月簽訂的三年基礎合同中的第一個一年期權期。這份合同支持DLA的防僞緩解計劃，以及針對FSC 5962微電路的產品驗證和測試計劃。該合同的無限制交付合同價值爲104萬美元，執行期限長達五年。行使期權年份將繼續應用DNA公司對DLA的防僞緩解計劃的支持，該支持已經自2014年以來運行。
"We are pleased to enable DLA to maintain program continuity in service of the nation's defense capabilities and further reinforce the application of our forensic DNA mark as a secure, high-resolution taggant to track provenance and ensure authenticity," said Judy Murrah, chief operating officer of Applied DNA.
“我們很高興能夠使DLA維持服務的連續性，進一步加強我們的法醫DNA標記作爲安全的、高分辨率的標記以跟蹤作源和確保真實性，”應用DNA公司的首席運營官Judy Murrah說。
About Applied DNA Sciences
關於Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
應用DNA科學公司是一家生物技術公司，正在開發生產和檢測去氧核糖核酸（“DNA”）的技術。通過利用聚合酶鏈式反應（“PCR”）實現DNA的生產和檢測，我們擁有三個主要的業務市場：（i）用於生產基於核酸的治療藥物的酶法合成人造DNA，並通過我們最近收購的Spindle Biotech，Inc.（“Spindle”）開發和銷售專有的RNA聚合酶（“RNAP”）以用於生產mRNA治療劑；（ii）分子診斷和遺傳測試服務中的DNA和RNA檢測；以及（iii）用於工業供應鏈安全服務的DNA的生產和檢測。
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
請訪問adnas.com了解更多信息。關注我們的X和領英。加入我們的郵件列表。
Forward-Looking Statements
前瞻性聲明
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the unknown future demand by the U.S. Defense Logistics Agency for its supply chain traceability service, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023 and Quarterly Report on Form 10-Q filed on February 8, 2024, and May 10, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
應用DNA在本新聞稿中所作的聲明可能具有"前瞻性"性質，依據1933年證券法第27A條、1934年證券交易法第21E條和1995年私人證券訴訟改革法。前瞻性陳述描述了應用DNA的未來計劃、預測、戰略和預期，並基於假設和涉及多種風險和不確定性，其中許多是應用DNA無法控制的。根據其淨虧損歷史、有限的財務資源、美國國防物資局對其供應鏈可追溯性服務的未知未來需求以及應用DNA的SEC報告和狀態表，實際結果可能會因各種因素而異，包括其修訂後於2023年12月7日提交的年度10-K形式的報告，以及於2024年2月8日、5月10日提交的季度10-Q形式的報告以及其他提交給SEC的報告，這些報告可在www.sec.gov上獲取。除非法律另有規定，否則應用DNA不承擔公開更新任何前瞻性聲明以反映新信息、事件或情況或反映突發事件的義務。
Contacts:
聯繫人：
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web:
Twitter: @APDN
Applied DNA Sciences
投資者關係聯繫人：Sanjay M. Hurry，917-733-5573，sanjay.hurry@adnas.com
網站：
Twitter：@APDN
SOURCE: Applied DNA Sciences, Inc.
SOURCE: Applied DNA Sciences, Inc.
譯文內容由第三人軟體翻譯。